Patients were randomly assigned to groups treated with telaprevir @ mg twice daily or @ mg every @ hours plus peginterferon alfa-@a and ribavirin for @ weeks ; patients were then treated with peginterferon alfa-@a and ribavirin alone for @ weeks if their level of HCV RNA at week @ was < @ IU/mL or for @ weeks if their level was higher .